Wunderlich Securities Comments on Abiomed

Wunderlich Securities provided color on Abiomed ABMD in a research report published today. Wunderlich Securities has previously given Abiomed a Buy rating. In the report, Wunderlich Securities states, "Abiomed (ABMD-$16.42, Buy) received a warning letter from the FDA on June 10, identifying three separate issues with the company's marketing of the Impella 2.5 device. While we clearly don't dismiss or minimize the potential significance of an FDA warning letter, we see no impact from the letter from a practical standpoint, and believe the issues identified by the FDA should be fairly easy for the company to resolve fairly quickly." Shares of Abiomed were trading at $15.80 at the time of posting, down 3.78% from Monday's market close.